Iqvia Holdings Inc (N:IQV)

Business Focus: Biotechnology & Medical Research

Jul 14, 2020 08:00 am ET
IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine
IQVIA™ (NYSE:IQV) has announced its collaboration with AstraZeneca (LON: AZN) to accelerate development of a potential new vaccine for COVID-19. This joint initiative is part of the U.S. government’s recently announced Operation Warp Speed project.
Jul 08, 2020 04:15 pm ET
IQVIA to Announce Second-Quarter Results on July 22, 2020
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will announce its second-quarter financial results before the market opens on Wednesday, July 22, 2020. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Jul 02, 2020 08:00 am ET
IQVIA Collaborates with LMC Manna Research to Launch the Largest Clinical Investigation Site in Canada
IQVIA™ (NYSE: IQV) today announced its strategic alliance with LMC Manna Research, the largest network of fully owned and integrated clinical research sites in Canada, to launch IQVIA’s first Prime Site in Canada. This adds to our network of more than 980 Prime and Partner clinical sites globally, which are sites with special designation assuring pharmaceutical and biotech companies their clinical trials will take place in premier investigative research centers with recognized professionals and with infrastructure focused on innovation and research development for patients.
Jun 10, 2020 05:58 pm ET
IQVIA Announces Pricing of Offering of Senior Notes
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of €711,000,000 in aggregate principal amount of senior notes due 2028 (the “Notes”). The proceeds from the Notes offering will be used to redeem all of the Issuer’s outstanding 3.500% senior notes due 2024, including the payment of premiums in respect thereof, to repay a portion of the existing borrowings under the Issuer’s revolving credit facility and to pay fees and expenses related to the Notes offering.
Jun 03, 2020 08:00 am ET
Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Improves Oncology’s Standard of Care with Genomics Technology Collaboration
Q2 Solutions, a leading clinical trial laboratory services organization resulting from an IQVIA and Quest Diagnostics joint venture, today announced its partnership with Thermo Fisher Scientific to use the Ion Torrent Genexus System, the first fully integrated, next-generation sequencing (NGS) platform, to deliver clinical trial lab results economically with unprecedented speed.
May 21, 2020 08:00 am ET
IQVIA Launches the First Solution to Address the Unique Business and Compliance Needs of Healthcare Professionals as Part of Its OCE Suite
IQVIA™ (NYSE: IQV) today announced the launch of HCP/O Engagement Management, the industry’s first end-to-end, orchestrated healthcare professional/organization (HCP/O) solution that enables the planning, management, contracting, and payment of HCP/Os globally.
May 20, 2020 08:00 am ET
IQVIA Collaborates with Australian Medical Research Institute on COVID-19 Study to Support Frontline Healthcare Workers
IQVIA™ (NYSE: IQV) today announced that the Walter and Eliza Hall Institute of Medical Research, a leading biomedical research organization in Australia, has selected IQVIA to manage COVID SHIELD, a Phase II/III ra
Apr 29, 2020 09:20 am ET
IQVIA Joins UK Government Collaboration to Provide Single Research Platform to Speed Development of New COVID-19 Treatments
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry, has joined the ACCORD-2 collaboration, which will fast-track development of new treatments for COVID-19. IQVIA will provide a single research platform across the United Kingdom to facilitate multiple clinical trials regardless of sponsor. This strategic alliance will examine the effectiveness of repurposed medicines, potential new drugs, and unlicensed therapies for treating COVID-19 patients.
Apr 28, 2020 07:00 am ET
IQVIA Reports First-Quarter 2020 Results; Issues Second-Quarter 2020 Guidance and Updates Full-Year 2020 Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2020.
Apr 07, 2020 09:28 am ET
IQVIA Launches Broad, Open COVID-19 Registry Platform to Advance Understanding, Collaboration, and Research
IQVIA™ (NYSE: IQV), a leader in Human Data Science, today announced the launch of its COVID Active Research Experience (CARE) Project at helpstopcovid19.com. The IQVIA CARE Project is an opt-in registry available to anyone – to advance understanding of COVID-19 through shared information about disease prevalence, symptom progression, and treatmen
Apr 06, 2020 07:00 pm ET
IQVIA Launches First Technology-Enabled COVID-19 Trial Matching Solution within the U.S. to Accelerate Treatment and Vaccine Development
IQVIA™ (NYSE: IQV), a leader in Human Data Science, today announced its new technology-enabled COVID-19 Trial Matching Tool at c19trials.com, which is one of the world’s first online platforms that matches individuals with specific COVID-19 studies to accelerate clinical research projects.
Apr 03, 2020 07:02 am ET
ObvioHealth Launches Virtual COVID-19 Symptoms & Immune Response Registry
SINGAPORE and NEW YORK, April 3, 2020 /PRNewswire/ -- ObvioHealth, a digital research company, announces the launch of a registry to monitor COVID-19 prevalence, symptoms and immune response in the United States over the coming 12 months....
Apr 02, 2020 08:29 pm ET
IQVIA Provides Update on Business Conditions in Light of COVID-19 and Provides Revised First-quarter 2020 Guidance; IQVIA will announce first-quarter results and update full-year 2020 guidance on Apri
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today updated its first-quarter 2020 guidance and provided a business update in light of the global COVID-19 crisis.
Mar 24, 2020 08:00 am ET
Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Collaborates with University of Texas Medical Branch to Help Accelerate Development of COVID-19 Vaccines
Q2 Solutions, a leading clinical trial laboratory services organization resulting from an IQVIA and Quest Diagnostics joint venture, today announced its collaboration with the University of Texas Medical Branch (UTMB) to develop a novel assay for COVID-19 (SARS-CoV-2) tests, an essential tool for rapid development of a Coronavirus vaccine. Once a viable assay is developed, Q2 Solutions labs will produce it for use in clinical trials to determine the effectiveness of a COVID-19 vaccine.
Feb 20, 2020 08:49 am ET
IQVIA Launches Avacare Clinical Research Network to Increase Patients’ Clinical and Research Options
IQVIA™ (NYSE: IQV), a leader in human data science, today announced the launch of Avacare Clinical Research Network™, a technology-based global site network that opens opportunities for more clinical trials at experienced clinical and research sites. Avacare’s unique analytical tools help sites in Avacare’s network match patients to clinical trials faster and more effectively.
Feb 13, 2020 04:41 pm ET
IQVIA Announces Repurchase of Common Stock
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that it has agreed to purchase an aggregate of 1,000,000 shares (the “Shares”) of its common stock in a private transaction from certain of its existing stockholders (the “Repurchase”). In addition to the Repurchase, affiliates of TPG Global, LLC, investment funds associated with Bain Capital Investors, LLC and CPP Investment Board Private Holdings Inc. informed IQVIA that they have sold 4,000,000 shares of IQVIA’s common stock pursuant to Rule 144 under the Securities Act of 1933, as amended, for a total of 5,000,000 shares.
Feb 12, 2020 07:00 am ET
IQVIA Reports Fourth-Quarter and Full-Year 2019 Results Issues First-Quarter and Full-Year 2020 Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter and year ended December 31, 2019.
Feb 03, 2020 08:00 am ET
IQVIA Launches FluSTAR Mobile App to Help Consumers Manage Their Health During Flu and Cold Season
IQVIA™ (NYSE: IQV) today announced the launch of the FluSTAR mobile application to help consumers understand and track flu and cold severity this winter. IQVIA’s FluStar app uses near real-time updates complied at www.FluSTAR.com, for current illness information for every ZIP code in the country, accessible from any mobile device.
Jan 30, 2020 08:00 am ET
IQVIA’s Breakthrough Natural Language Processing Platform Receives 2019 Fierce Innovation Award
IQVIA™ (NYSE: IQV) announced today that its Linguamatics Natural Language Processing (NLP) platform has been selected as the winner in Questex’s 2019 Fierce Innovation Awards — LifeSciences Edition in the Data Analytics/Business Intelligence category. The Fierce Innovation Awards is a peer-reviewed awards program from the publisher of FierceBiotech and FiercePharma and recognizes IQVIA Linguamatics NLP platform as an industry-leading product.
Jan 29, 2020 04:15 pm ET
IQVIA to Announce Fourth-Quarter and Full-Year 2019 Results and Issue 2020 Guidance on February 12, 2020
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will announce its fourth-quarter and full-year 2019 financial results and issue 2020 guidance before the market opens on Wednesday, February 12, 2020. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Jan 23, 2020 08:00 am ET
AP-HP, Europe’s Leading Clinical Research Center, and IQVIA Collaborate to Launch the Largest Clinical Investigation Site in Europe
Assistance Publique – Hôpitaux de Paris (AP-HP), Europe's leading clinical research center, joins IQVIA™, the global health technology and human data science company, to launch the Paris Prime Site for clinical trials. This AP-HP partnership represents IQVIA’s second Prime Site within France, as well as the 43rd globally, the 18th within Europe and largest research facility of its kind within that region.
Jan 21, 2020 08:00 am ET
IQVIA Named to FORTUNE’s 2020 List of “World’s Most Admired Companies”
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) has been named to FORTUNE magazine’s “World’s Most Admired Companies” list. IQVIA has received this distinction every year, since its inception, following the merger between IMS Health and Quintiles in 2016. IQVIA is recognized in FORTUNE’s Healthcare: Pharmacy and Other Services category with high marks regarding efficient use of corporate assets, management quality, effectiveness in conducting business globally, and long-term investment value.
Dec 19, 2019 08:00 am ET
AstraZeneca Selects IQVIA OCE to Help Further its Digital Focus
IQVIA™ (NYSE: IQV) today announced that AstraZeneca (LON: AZN) has selected IQVIA Technologies’ Orchestrated Customer Engagement (OCE) platform to further its digital agenda and establish its “Field of the Future.”
Oct 30, 2019 07:00 am ET
IQVIA Reports Third-Quarter 2019 Results
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter ended September 30, 2019.
Oct 16, 2019 04:15 pm ET
IQVIA to Announce Third-Quarter 2019 Results on October 30, 2019
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will announce its third-quarter 2019 financial results before the market opens on Wednesday, October 30, 2019. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Daylight Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Oct 02, 2019 08:00 am ET
IQVIA Launches Orchestrated Patient Engagement
IQVIA™ (NYSE: IQV) today announced the launch of Orchestrated Patient Engagement (OPE), a new cloud-based software as a service (SaaS) solution that helps close the gap between life sciences companies and patients. The OPE SaaS solution is powered by Belong.Life technology to allow life sciences customers to facilitate interactions and gain insights from patients who opt-in
Oct 01, 2019 08:00 am ET
IQVIA Launches IQVIA Consumer Health to Meet the Growing Business Needs of the Retail Health Sector
IQVIA™ (NYSE:IQV) today announced the launch of IQVIA Consumer Health, dedicated to supporting companies to drive innovation, operate more efficiently, optimize expanding product portfolios, and revitalize existing brands. IQVIA Consumer Health applies deep domain expertise, global and local regulatory intelligence, and insights that transform data into actionable strategies. This unique suite of solutions employs advanced technologies to help customers make quick, precise decisions to drive healthcare forward in a highly competitive market.
Sep 18, 2019 08:00 am ET
IQVIA Collaborates with Cancer Researchers to Advance Use of Real World Evidence
IQVIA™ (NYSE:IQV) is proud to announce its collaboration with Friends of Cancer Research in a cross-industry effort to advance acceptance and drive future uses of real world evidence (RWE). This research helps confirm that clinical benefits seen for therapies in clinical trials were consistent with the benefits of those treatments within real world settings. RWE comprises dynamic data including assets such as EMR, hospital, pharmacy, and claims sources, as well as genomics, mobile health, and patient reported outcomes. The project is part of a Friends of Cancer Research initiative that is work
Sep 17, 2019 08:00 am ET
IQVIA MedTech Launches Enhanced EQMS including EU MDR Support
IQVIA™ (NYSE:IQV) today announced the launch of its latest release of the IQVIA SmartSolve® Enterprise Quality Management Solution (EQMS). This marks the world’s first EQMS to provide expanded quality, regulatory, and safety compliance support for the new European Union Medical Device Regulation 2017/745/EU (EU MDR). This includes support for the new Manufacturer Incident
Aug 26, 2019 08:00 am ET
IQVIA Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that it received notice of an unsolicited “mini-tender” offer by TRC Capital Investment Corporation (TRC Capital) to purchase up to one million IQVIA common shares at a price of $148.35 per share in cash. The offering price is 4.42 percent below the closing price per share of IQVIA’s common stock on August 16, 2019, the last trading day before the offer was commenced, and 3.13 percent below the closing price per share of IQVIA’s common stock on August 23, 2019. The offer is for approximately 0.51 percent of the common shares outstanding.
Aug 21, 2019 04:15 pm ET
IQVIA to Participate in Baird 2019 Global Healthcare Conference on September 4, 2019
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Baird 2019 Global Healthcare Conference in New York, NY on Wednesday, September 4, 2019 at 9:40 a.m. ET.
Aug 15, 2019 08:00 am ET
IQVIA Launches Patient Portal to Transform the Clinical Trial Experience
IQVIA™ (NYSE:IQV) announces its launch of the IQVIA Patient Portal, a global web-based solution built on a leading health cloud platform. This innovative tool enables increases in clinical trial patient recruitment, engagement and retention by ensuring transparency and collaboration before, during, and after a clinical study.
Aug 08, 2019 04:40 pm ET
IQVIA Announces Repurchase of Common Stock
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that it has agreed to purchase an aggregate of 1,000,000 shares (the “Shares”) of its common stock in a private transaction from certain of its existing stockholders (the “Repurchase”). In addition to the Repurchase, affiliates of TPG Global, LLC, investment funds associated with Bain Capital Investors, LLC and CPP Investment Board Private Holdings Inc. informed IQVIA that they have sold 4,000,000 shares of IQVIA’s common stock pursuant to Rule 144 under the Securities Act of 1933, as amended, for a total of 5,000,000 shares.
Aug 05, 2019 08:00 am ET
IQVIA Named Real World Evidence Market Leader
IQVIA™ (NYSE:IQV) today announced that a new Life Science Strategy Group (LSSG) report named IQVIA the market leader in real world data and real world evidence services. One hundred biopharma companies involved in drug development and commercialization participated in this latest LSSG survey. Respondents overwhelmingly chose IQVIA as the thought leader and expert across r
Aug 01, 2019 08:15 am ET
IQVIA’s Cynthia Verst Honored on 2019 PharmaVOICE 100 List
IQVIA™ (NYSE:IQV) today announced that Cynthia Verst, IQVIA’s president, Design and Delivery Innovation, Research & Development Solutions, has been named to PharmaVOICE magazine’s annual list of the 100 most influential and inspiring individuals within the life sciences industry.
Jul 31, 2019 10:22 am ET
Spruce Point Capital Management Releases A Strong Sell Research Opinion On Penumbra, Inc. (NYSE: PEN)
NEW YORK, July 31, 2019 /PRNewswire/ -- Report entitled "Sucking Wind" outlines how Penumbra faces 40-55% downside risk to approximately $85.00 to $110.00 per share after accounting for a wave of new competition, deeply misunderstood market share loss, pricing pressure and a contracting valuation premium as growth slows....
Jul 30, 2019 04:10 pm ET
IQVIA Announces Pricing of Offering of Senior Notes
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of €720,000,000 in aggregate principal amount of senior notes due 2028 (the “Notes”). The net proceeds from the Notes offering, together with available cash, will be used to redeem the Issuer’s outstanding 4.875% senior notes due 2023 and to pay fees and expenses related to the Notes offering.
Jul 29, 2019 03:00 am ET
IQVIA Announces Offering of Senior Notes
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $800,000,000 equivalent in gross proceeds through an offering of euro-denominated senior notes due 2028. IQVIA also announced that the Issuer delivered a conditional notice of redemption with respect to its outstanding 4.875% senior notes due 2023 (the “4.875% Notes”).
Jul 24, 2019 07:00 am ET
IQVIA Holdings, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 24, 2019 / IQVIA Holdings, Inc. (NYSE: IQV) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 24, 2019 at 9:00 AM Eastern Time.
Jul 24, 2019 07:00 am ET
IQVIA Reports Second-Quarter 2019 Results, Raises Full-Year Revenue and Adjusted Diluted EPS Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2019.
Jul 23, 2019 08:00 am ET
IQVIA Awarded Frost & Sullivan’s Life Sciences Product Leadership Award for Its Advanced Quality Management Technology Solution
IQVIA™ (NYSE:IQV) today announced it has received the Frost & Sullivan’s 2018 Global Enterprise Quality Management Solutions for Life Sciences Product Leadership award. IQVIA Technologies’ SmartSolve®, a best-in-class, integrated enterprise quality management solution (EQMS), was selected for its unique ability to address the needs of life sciences companies in qualit
Jul 22, 2019 08:00 am ET
IQVIA Named to Forbes 2019 List of America’s Best Employers for Women
IQVIA Holdings Inc. (“IQVIA™”) (NYSE: IQV) has been named to the Forbes 2019 list of America’s Best Employers for Women. Forbes joined with market research firm Statista to identify the companies liked most by female employees based on various workplace criteria that included pay equity, diversity, family support, working conditions, and parental leave.
Jul 15, 2019 04:40 pm ET
Martin Marietta Appoints New Member to Board of Directors
Martin Marietta Materials, Inc. (NYSE:MLM) today announced the appointment of Thomas (Tom) H. Pike as an independent member to its Board of Directors, effective July 15, 2019. With Mr. Pike’s appointment, the Martin Marietta Board is comprised of...
Jul 09, 2019 04:15 pm ET
IQVIA to Announce Second-Quarter 2019 Results on July 24, 2019
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will announce its second-quarter 2019 financial results before the market opens on Wednesday, July 24, 2019. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Daylight Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Jun 25, 2019 08:00 am ET
IQVIA Introduces Patient Centered Endpoints Solution with Transformative eCOA Technology Platform
IQVIA™ (NYSE:IQV) today announced the launch of the Patient Centered Endpoints (PCE) solution, an innovative science and technology-enabled approach that captures quantified evidence of patients’ experiences during clinical trials and real world studies. This disruptive technology enables trial sponsors to better understand the patients’ experiences on various therapies, reduce study implementation timelines, and enhance data transparency.
Jun 17, 2019 08:00 am ET
Chiesi Group Selects IQVIA’s OCE Technology Platform to Develop a Customer Centric Ecosystem across the Organization
IQVIA™ (NYSE:IQV) today announced that Chiesi Farmaceutici, the international research-focused healthcare Group (Chiesi Group) is leveraging IQVIA Technologies’
Jun 13, 2019 04:15 pm ET
IQVIA’s OCE Technology Platform Selected by Ferring Pharmaceuticals
IQVIA™ (NYSE:IQV) today announced that Ferring Pha
Jun 04, 2019 08:00 am ET
IQVIA’s OCE Technology Platform Selected by Zambon to Establish a Global Multichannel Commercial Engagement Model for OTC Business
IQVIA™ (NYSE:IQV) today announced that Zambon, an Italian multinational pharmaceutical and fine-chemical company, has selected
May 30, 2019 04:15 pm ET
IQVIA Real World Capabilities and Expertise Support Path to Label Expansion
IQVIA™ (NYSE:IQV) is pleased to have provided support towards the approval from the U.S. Food and Drug Administration to expand the indications for IBRANCE® (palbociclib) in combination with an aromatase inhibitor or fulvestrant to include the treatment of men with hormone receptor-positive (HR+), human epidermal growth factor receptor
May 30, 2019 08:00 am ET
IQVIA™ Institute for Human Data Science Releases Global Oncology Trends 2019 Study: Record Number of Cancer Drugs Launched in 2018 across 17 Indications
The IQVIA™ Institute for Human Data Science found in its latest report, Global Oncology Trends 2019: Therapeutics, Clinical Development and Health System Implications, that in 2018 a record-setting 15 new active substance (NAS) oncology treatments with 17 indications, including one tissue-agnostic therapy, launched in the U.S. Those 2018 debuts bring the total number of new oncology therapeutics launched since 2013 to 57 covering 89 approved indications for 23 different tumor types.
May 28, 2019 08:00 am ET
IQVIA Women Leaders Recognized for Their Outstanding Contributions to the Advancement of Healthcare
IQVIA™ (NYSE:IQV) today announced that three of the company’s women leaders have received significant awards for their leadership, vision and strategic abilities to drive disruptive technologies, improve health outcomes, and advance innovation.
May 23, 2019 04:15 pm ET
IQVIA to Participate in William Blair Growth Stock Conference on June 5, 2019
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ari Bousbib, chairman and chief executive officer, will speak at the William Blair 39th Annual Growth Stock Conference in Chicago, IL on Wednesday, June 5, 2019 at 10:40 a.m. CT / 11:40 a.m. ET.
May 14, 2019 04:15 pm ET
IQVIA to Host Financial Analyst and Investor Conference on June 18, 2019
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will host an Analyst and Investor Conference in New York City on Tuesday, June 18, 2019. Management will provide an update on the business, with presentations starting at 9:00 a.m. ET and concluding at approximately 1:00 p.m. ET. Registration is required to attend the event.
May 13, 2019 04:15 pm ET
IQVIA Launches IQVIA MedTech Dedicated to Medical Device and Diagnostics Industry
IQVIA™ (NYSE:IQV) today announced the launch of IQVIA MedTech and its dedicated industry focused solutions and services for the medical device and in vitro diagnostics market, and for companies with combination products. IQVIA MedTech empowers companies to orchestrate operations across their entire product lifecycle, from concept-to-market
May 09, 2019 08:00 am ET
IQVIA™ Institute for Human Data Science Releases 2019 Medicines Report on U.S. Drug Consumption; U.S. Rx Opioid Volume Declined 17% in 2018 – Largest Single-Year Drop Ever Recorded
The latest report from the IQVIA™ Institute for Human Data Science found prescription opioid dosage volume — as defined by morphine milligram equivalents, or MMEs — declined 17 percent in 2018, marking the single-largest annual drop ever recorded within the U.S. market.
May 07, 2019 05:17 pm ET
IQVIA Announces Pricing of Offering of Senior Notes
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $1,100,000,000 in aggregate principal amount of senior notes due 2027 (the “notes”). The net proceeds from the notes offering will be used to repay existing borrowings under the Issuer’s revolving credit facility, to pay fees and expenses related to the notes offering and for other general corporate purposes.
May 07, 2019 07:32 am ET
IQVIA Announces Offering of Senior Notes
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $1,100,000,000 in gross proceeds through an offering of senior notes due 2027. The net proceeds from the notes offering will be used to repay existing borrowings under the Issuer’s revolving credit facility, to pay fees and expenses related to the notes offering and for other general corporate purposes. The consummation of the notes offering is subject to market and other customary conditions.
May 01, 2019 07:00 am ET
IQVIA Reports First-Quarter 2019 Results, Reaffirms Full-Year Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2019.
Apr 25, 2019 08:00 am ET
IQVIA’s OCE Technology Platform Selected by Salehiya Medical to Enhance Customer Experience in Saudi Arabia
IQVIA™ (NYSE:IQV) today announced that Salehiya Medical, a leading Saudi Arabian healthcare distribution company, has selec
Apr 24, 2019 08:00 am ET
United Health Products Retains IQVIA to Conduct U.S. Market Commercialization Study of HemoStyp® in Support of Société Générale’s Strategic Review
United Health Products, Inc. (OTC: UEEC), (“UHP” or “the company”), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it had retained IQVIA Inc. to conduct a U.S....
Apr 23, 2019 08:00 am ET
IQVIA Institute for Human Data Science Study: Record 59 New U.S. Drugs Launched in 2018, Success Rates Fall, R&D Trends Could Improve Productivity by 2023
Ongoing changes in the clinical development process led to a record number of drug approvals in 2018, with 59 novel treatments reaching patients in the United States alone. During the next five years, trial productivity will be heavily influenced by key trends, including wider use of biomarkers, pre-screened patient pools, regulatory shifts and application of artificial intelligence and predictive analytics.
Apr 17, 2019 04:15 pm ET
IQVIA to Announce First-Quarter 2019 Results on May 1, 2019
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), will announce its first-quarter 2019 financial results before the market opens on Wednesday, May 1, 2019. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Daylight Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Apr 09, 2019 10:30 am ET
IQVIA Releases Enhanced OCE Capability
IQVIA™ (NYSE: IQV) today announced the expansion of
Mar 06, 2019 06:00 am ET
IQVIA Announces Pricing of Secondary Public Offering
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) announced today the pricing of an underwritten, secondary public offering of 5,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC and investment funds associated with Bain Capital Investors, LLC (the “Selling Stockholders”), at a price to the public of $141.00 per share. IQVIA intends to repurchase from the underwriters 1,000,000 shares (the “Repurchase”).
Mar 05, 2019 04:52 pm ET
IQVIA Announces Launch of Secondary Public Offering and Repurchase of Common Stock
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) announced today the launch of an underwritten, secondary public offering of 5,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC and investment funds associated with Bain Capital Investors, LLC (the “Selling Stockholders”), of which IQVIA intends to repurchase from the underwriter 1,000,000 shares (the “Repurchase”).
Mar 05, 2019 08:00 am ET
IQVIA Launches E360 Genomics
IQVIA™ (NYSE: IQV) today announced the launch of a patented technology platform that advances real-world research and protects genomic data privacy. E360™ Genomics, a scalable, privacy-preserving genotypic-phenotypic database solution, provides an efficient way to conduct genomic research with genomic and clinical databases.
Mar 05, 2019 07:45 am ET
Market Trends Toward New Normal in Ritchie Bros. Auctioneers, Empire State Realty Trust, Synergy Resources, IQVIA, Intrexon, and Denbury Resources — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ritchie Bros. Auctioneers Incorporated (NYSE:RBA), Empire State Realty...
Mar 04, 2019 04:15 pm ET
IQVIA’s FluSTAR Online Dynamic Platform Helps Consumers Track Local Rates of Flu, Allergy and Asthma
IQVIA™ (NYSE:IQV), a leader in human data science, provides consumers with quick and easy access to seasonal suffering data, giving them unique insights into important health related information. Recent data show that flu season is hitting hard in several key markets.
Feb 28, 2019 04:15 pm ET
IQVIA to Present at the Barclays Global Healthcare Conference on March 12, 2019
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), announced today that Michael McDonnell, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 12, 2019 at 1:35 p.m. EDT.
Feb 21, 2019 08:00 am ET
Carol J. Burt Joins IQVIA Board of Directors
IQVIA™ (NYSE:IQV) today announced the appointment of Carol J. Burt to its board of directors, effective today. A principal of private investment firm Burt-Hilliard Investments for more than a decade, Burt is a former executive officer of WellPoint, Inc. (now Anthem, Inc.), lastly as Senior Vice President, Corporate Finance and Development, an
Feb 14, 2019 07:00 am ET
IQVIA Reports Fourth-Quarter and Full-Year 2018 Results, Issues First-Quarter and Full-Year 2019 Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter and year ended December 31, 2018.
Feb 11, 2019 08:00 am ET
IQVIA Introduces RIM Smart, the Industry’s First Fully Integrated, End-to-End Regulatory Information Management System
IQVIA™ (NYSE:IQV) today announced the launch of IQVIA RIM Smart, the first fully integrated, cloud-based, end-to-end regulatory information management solution for life sciences. Designed to leverage artificial intelligence (AI) and machine learning (ML), IQVIA Technologies’ new solution enables intellige
Feb 08, 2019 08:10 am ET
Recent Analysis Shows Amerco, McKesson, Ophthotech, IQVIA, Highwoods Properties, and ABM Industries Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Amerco (NASDAQ:UHAL), McKesson Corporation (NYSE:MCK), Ophthotech...
Feb 04, 2019 09:59 am ET
IQVIA Launches IQVIA Biotech, Dedicated to Emerging Biotech and Biopharma Industry
IQVIA™ (NYSE:IQV) today announced the launch of IQVIA™ Biotech and its new approach to delivering tailored clinical and commercial solutions for small biotech and biopharma companies. This solutions suite, supported by more than 1,000 dedicated employees, will deliver simplified operating procedures, specialized teams, and services
Jan 31, 2019 08:00 am ET
IQVIA Launches Next Generation Site Portal Technology Capabilities to Streamline Clinical Trial Communications
IQVIA™ (NYSE:IQV) today launched two new capabilities to support clinical teams more easily and quickly share cross-trial training materials and safety notifications. These features were co-designed, tested, and are now in use by two of the top-five pharmaceutical companies.
Jan 30, 2019 06:45 am ET
IQVIA to Announce Fourth-Quarter and Full-Year 2018 Results and Issue 2019 Guidance on February 14, 2019
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), will announce its fourth-quarter and full-year 2018 financial results and issue 2019 guidance before the market opens on Thursday, February 14, 2019. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Jan 29, 2019 08:00 am ET
IQVIA Institute for Human Data Science Study: Global Medicine Spending Exceeds $1.5 Trillion by 2023 as Spending Growth Steadies
Total spending on medicines is expected to top $1.5 trillion by 2023, up 50 percent from 2014, even as annual growth moderates at 3-6 percent on an annual compound basis compared to 6.3 percent over the past five years, according to new research released from the IQVIA™ Institute for Human Data Science. The study found global drug spending reached $1.2 trillion in 2018, with the key drivers of growth during the next five years to be the United States and pharmerging markets with 4-7 percent and 5-8 percent compound annual growth respectively.
Jan 22, 2019 07:30 am ET
IQVIA Named to FORTUNE’s 2019 List of “World’s Most Admired Companies”
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) has once again been named to FORTUNE magazine’s “World’s Most Admired Companies” list. IQVIA received the distinction in FORTUNE’s Healthcare: Pharmacy and Other Services category with high marks in quality of management, effectiveness in conducting business globally, wise use of corporate assets, and value as a long-term investment.
Jan 14, 2019 07:35 am ET
Report: Exploring Fundamental Drivers Behind IQVIA, The Ultimate Software Group, Brightcove, Selective Insurance Group, XPO Logistics, and Magellan Midstream Partners — New Horizons, Emerging Trends,
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of IQVIA Holdings Inc. (NYSE:IQV), The Ultimate Software Group, Inc....
Jan 08, 2019 08:00 am ET
IQVIA Announces Comprehensive Multi-Tenant SaaS Safety Platform for Life Sciences Industry
IQVIA™ (NYSE:IQV) today announced its development of a Software as a Service (SaaS) safety platform that scales to address the drug safety and surveillance challenges of life sciences organizations, ranging from emerging biopharma to large pharmaceutical companies. This SaaS solution is built to allow access from multiple users, across multip
Jan 07, 2019 08:00 am ET
IQVIA’s Orchestrated Customer Engagement (OCE) Solution Adopted by More than 30 Life Sciences Companies in First Year of Launch
IQVIA™ (NYSE:IQV) today announced that more than 30 life sciences companies have selected Orchestrated Customer Engagement (OCE) as their commercial solution in the 12 months since the groundbreaking technology
Dec 06, 2018 08:00 am ET
IQVIA Named Best Contract Research Organization Full-Service Provider in 2018 Scrip Awards
IQVIA™ (NYSE:IQV) today announced that it was awarded the 2018 Scrip Award for Best Contract Research Organization — Full-Service Provider. This marks the seventh time in the last 10 years that the company has received this award.
Dec 04, 2018 12:00 pm ET
Orchestra BioMed™ Appoints C. Evan Ballantyne as Chief Financial Officer
Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that it has appointed Evan Ballantyne as its Chief...
Nov 30, 2018 08:00 am ET
IQVIA Announces Pricing of Secondary Public Offering
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) announced today the pricing of an underwritten, secondary public offering of 6,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc. and investment funds associated with Bain Capital Investors, LLC (the “Selling Stockholders”), at a price to the public of $124.25 per share. IQVIA intends to repurchase from the underwriter 2,000,000 shares (the “Repurchase”).
Nov 29, 2018 04:47 pm ET
IQVIA Announces Launch of Secondary Public Offering and Repurchase of Common Stock
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) announced today the launch of an underwritten, secondary public offering of 6,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc. and investment funds associated with Bain Capital Investors, LLC (the “Selling Stockholders”), of which IQVIA intends to repurchase from the underwriter 2,000,000 shares (the “Repurchase”).
Nov 29, 2018 08:00 am ET
IQVIA’s OCE Technology Platform Selected by Napo Pharmaceuticals to Increase Commercial Efficiency
IQVIA™ (NYSE:IQV) today announced that Napo Pharmaceuticals, Inc. (Napo), a wholly-owned subsidiary of Jaguar Health, Inc., has selected
Nov 27, 2018 08:00 am ET
IQVIA’s Orchestrated Customer Engagement Selected by Novo Nordisk International Operations
IQVIA™ (NYSE:IQV) today announced that Novo Nordisk, a global healthcare company with nearly a century of innovation and leadership in diabetes care, has selected IQVIA’s market-leading Orchestrated Customer Engagement platform for deployment across Novo Nordisk International Operations.
Nov 20, 2018 08:00 am ET
Adhera Therapeutics Selects IQVIA’s OCE Technology Platform to Support Commercial Excellence
IQVIA™ (NYSE:IQV) today announced that Adhera Therapeutics Inc. (OTCQB:ATRX) has selected
Nov 15, 2018 08:00 am ET
IQVIA Launches Digital ICF Author, a SaaS eConsent Tool to Transform the Informed Consent Process
IQVIA™ (NYSE:IQV) announced today the launch of Informed Consent Form (ICF) Author, a SaaS eConsent tool for use in clinical trials. The online portal allows sponsors, sites, and contract research organizations (CROs) to produce their own ICFs for delivery via eConsent or traditional paper.
Nov 06, 2018 04:15 pm ET
IQVIA to Present at the Credit Suisse Annual Healthcare Conference on November 13, 2018
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), announced today that Michael McDonnell, executive vice president and chief financial officer, will speak at the Credit Suisse 27th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 1:40 p.m. MST / 3:40 p.m. EST.
Nov 02, 2018 07:45 am ET
New Research: Key Drivers of Growth for Shutterfly, Aegion, Columbia Property Trust, Aduro Biotech, IQVIA, and Intelsat S.A — Factors of Influence, Major Initiatives and Sustained Production
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Shutterfly, Inc. (NASDAQ:SFLY), Aegion Corporation (NASDAQ:AEGN), Columbia...
Oct 22, 2018 07:00 am ET
IQVIA Reports Third-Quarter 2018 Results and Updates Full-Year 2018 Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter ended September 30, 2018. On January 1, 2018, IQVIA adopted ASC 606 “Revenue from Contracts with Customers” as required by the Financial Accounting Standards Board. Under this new standard, IQVIA recognizes revenue in the Research & Development Solutions segment on a percentage of completion basis. Additionally, ASC 606 requ
Oct 16, 2018 08:00 am ET
IQVIA’s Commercial Technology Suite for Global Deployment Selected by Roche
IQVIA (NYSE: IQV) today announced that the pharmaceuticals division of Roche (F. Hoffmann-La Roche Ltd) has selected IQVIA’s commercial technology suite for deployment across more than 100 markets. IQVIA’s Technologies suite includes the Orchestrated Customer Engagement (OCE) Sales/Marketing, Master Data Management (MDM), ePromo and Organizati
Oct 15, 2018 04:15 pm ET
IQVIA to Announce Third-Quarter 2018 Results on October 22, 2018
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), will announce its third-quarter 2018 financial results before the market opens on Monday, October 22, 2018. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Oct 11, 2018 07:35 am ET
Recent Analysis Shows RadNet, Electro Scientific Industries, Koppers, Momenta Pharmaceuticals, IQVIA, and Columbia Property Trust Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of RadNet, Inc. (NASDAQ:RDNT), Electro Scientific Industries, Inc....
Oct 04, 2018 08:00 am ET
IQVIA and Genomics England Launch the First Real-World Research Platform with Integrated Clinical and Genomic Data
IQVIA™ (NYSE:IQV) and Genomics England today announced a collaboration to develop a platform that will connect clinical and de-identified genomics data to accelerate treatment advancements for patients. This alliance will enable faster and more efficient drug research, more robust evidence to support treatment value, and greater access to personalized medicines.
Sep 20, 2018 08:00 am ET
IQVIA to Build Clinically-Focused Tech Solutions Suite for Life Sciences on Salesforce Health Cloud
IQVIA (NYSE: IQV) today announced the expansion of its alliance with Salesforce, the global leader in CRM and provider of Softwa
Aug 16, 2018 04:05 pm ET
Theramex Chooses IQVIA’s Orchestrated Customer Engagement
IQVIA™ (NYSE: IQV), a company dedicated to applying advanced analytics and technology in healthcare to help clients find better solutions for patients, and Theramex, an international pharmaceutical company dedicated to women’s health, today announced a global technology collaboration to integrate IQVIA’s market-leading Orchestrated Customer Engagement (OCE) platform into Theramex’s European commercial operations.
Aug 06, 2018 07:25 am ET
Detailed Research: Economic Perspectives on IQVIA, Intellia Therapeutics, Deluxe, Superior Industries International, The Navigators Group, and CAI International — What Drives Growth in Today's Competi
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of IQVIA Holdings Inc. (NYSE:IQV), Intellia Therapeutics, Inc. (NASDAQ:NTLA),...
Aug 02, 2018 04:15 pm ET
Medytox Selects IQVIA’s Enterprise Quality Management Platform, Including SmartSolve®, for Quality and Compliance Management
IQVIA™ (NYSE: IQV) today announced that the global biopharmaceutical company Medytox has selected IQVIA’s Enterprise Quality Management Solutions (EQMS) platform for quality and compliance management. The platform uniquely supports Medytox’s goals of meeting industry regulatory requirements and exceeding global quality standards.
Aug 01, 2018 08:30 am ET
IQVIA’s Jon Resnick Honored on 2018 PharmaVOICE 100 List
IQVIA (NYSE:IQV) today announced that Jon Resnick, IQVIA’s president, Real-World & Analytics Solutions, has been named to PharmaVOICE magazine’s annual list of the 100 most influential and inspiring individuals within the life sciences industry.
Jul 24, 2018 07:00 am ET
IQVIA Reports Second-Quarter 2018 Results and Raises Full-Year 2018 Revenue and Profit Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2018. On January 1, 2018, IQVIA adopted ASC 606 “Revenue from Contracts with Customers” as required by the Financial Accounting Standards Board. Under this new standard, IQVIA recognizes revenue in the Research & Development Solutions segment on a percentage of completion basis. Additionally, ASC 606 requires
Jul 10, 2018 04:15 pm ET
IQVIA to Announce Second-Quarter 2018 Results on July 24, 2018
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), will announce its second-quarter 2018 financial results before the market opens on Tuesday, July 24, 2018. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Jun 21, 2018 08:00 am ET
IQVIA Launches a Transformative Suite of Virtual Research Solutions
IQVIA (NYSE:IQV) announced today the launch of Virtual Research Solutions, a new suite of technology-led study options offering advances in patient-centric trial design and execution.
Jun 13, 2018 08:00 am ET
IQVIA Announces Pricing of Secondary Public Offering
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) announced today the pricing of an underwritten, secondary public offering of 12,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc., investment funds associated with Bain Capital Investors, LLC, and Dr. Dennis B. Gillings, CBE (the “Selling Stockholders”), at a price to the public of $103.50 per share. IQVIA intends to repurchase from the underwriter 4,000,000 shares (the “Repurchase”).
Jun 12, 2018 05:06 pm ET
IQVIA Announces Launch of Secondary Public Offering and Repurchase of Common Stock
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) announced today the launch of an underwritten, secondary public offering of 12,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc., investment funds associated with Bain Capital Investors, LLC, and Dr. Dennis B. Gillings, CBE (the “Selling Stockholders”), of which IQVIA intends to repurchase from the underwriter 4,000,000 shares (the “Repurchase”).
Jun 11, 2018 06:29 pm ET
IQVIA Announces Senior Secured Credit Facility Transaction to Refinance Existing Indebtedness
IQVIA Inc., a wholly-owned subsidiary of IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), today announced that it has placed approximately $1.65 billion of USD and EUR term B loans:
Jun 05, 2018 02:00 am ET
IQVIA Launches Commercial Content Management Solution IQVIA™ ePromo
IQVIA (NYSE:IQV), a company dedicated to applying advanced analytics and technology to help healthcare clients find better solutions for patients, today announced the launch of IQVIA™ ePromo, a new cloud-based content management technology solution. ePromo makes it easier for life sciences companies to manage their regulated promotional and medic
May 24, 2018 08:00 am ET
IQVIA™ Institute for Human Data Science Study: Spending on Cancer Meds in the U.S. Doubled from 2012-2017 – Expected to Double Again by 2022 to $100 Billion
The IQVIA™ Institute for Human Data Science found in its latest report, Global Oncology Trends 2018: Innovation, Expansion and Disruption, that spending on cancer drugs in the U.S. has doubled since 2012, reaching almost $50 billion in 2017, with two-thirds of the growth tied to drugs launched within the past five years. Those drug costs are expected to double again by 2022. Outside the U.S., oncology drug costs exceeded $60 billion in 2017, driven by new product launches and increased use of existing brands.
May 17, 2018 08:28 pm ET
PruGen Pharmaceuticals Selects IQVIA’s OCE Technology Platform to Advance Field Sales and Home Office Effectiveness
IQVIA™ (NYSE:IQV), a company dedicated to applying advanced analytics and technology to help healthcare clients find better solutions for patients, today announced that
May 17, 2018 08:10 pm ET
IQVIA Reaffirms Its Second-Quarter and Full-Year 2018 Guidance, Including Adjusted EPS Growth of 13.6% to 20.4% and 14.3% to 19.9%, Respectively
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reaffirmed its second-quarter and full-year 2018 guidance previously provided on May 2nd.
May 17, 2018 07:53 pm ET
IQVIA Holdings Inc. Provides Update on Secondary Offering
IQVIA Holdings Inc. (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, announced today that in light of recent market conditions, it and the selling stockholders will not proceed with the previously announced secondary public offering and concurrent repurchase of common stock.
May 16, 2018 02:57 pm ET
IQVIA Response to FDA Statement
IQVIA™ (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. We also provide a select set of services to the FDA and other government agencies. Recently, we made a correction to a kilogram conversion measurement in the United States IQVIA National
May 16, 2018 08:00 am ET
IQVIA Announces Pricing of Secondary Public Offering
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) announced today the pricing of an underwritten, secondary public offering of 10,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc., investment funds associated with Bain Capital Investors, LLC, Leonard Green & Partners, L.P., and Dr. Dennis B. Gillings, CBE and certain of his affiliates (the “Selling Stockholders”), at a price to the public of $101.85 per share. IQVIA intends to repurchase from t
May 15, 2018 04:51 pm ET
IQVIA Announces Launch of Secondary Public Offering and Repurchase of Common Stock
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) announced today the launch of an underwritten, secondary public offering of 10,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc., investment funds associated with Bain Capital Investors, LLC, Leonard Green & Partners, L.P., and Dr. Dennis B. Gillings, CBE and certain of his affiliates (the “Selling Stockholders”), of which IQVIA intends to repurchase from the underwriter 2,500,000 shares (the
May 08, 2018 04:15 pm ET
IQVIA to Present at the Bank of America Merrill Lynch Health Care Conference on May 15, 2018
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), announced today that Michael McDonnell, executive vice president and chief financial officer, will speak at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas on Tuesday, May 15, 2018 at 1:40 p.m. PDT / 4:40 p.m. EDT.
May 02, 2018 07:00 am ET
IQVIA Reports First-Quarter 2018 Results and Raises Full-Year 2018 Revenue Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2018. On January 1, 2018, IQVIA adopted ASC 606 “Revenue from Contracts with Customers” as required by the Financial Accounting Standards Board. Under this new standard, IQVIA recognizes revenue in the Research & Development Solutions segment on a percentage of completion basis. Additionally, ASC 606 requires
Apr 30, 2018 08:00 am ET
Recordati Selects IQVIA’s OCE Technology Platform and OneKey Information Services
IQVIA (NYSE:IQV), a company dedicated to applying advanced analytics and technology to help healthcare clients find better solutions for patients, and
Apr 26, 2018 08:10 am ET
Market Trends Toward New Normal in FormFactor, Corindus Vascular Robotics, Syntel, IQVIA Holdings, Hannon Armstrong Sustainable Infrastructure Capital, and Ennis — Emerging Consolidated Expectations,
NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FormFactor, Inc. (NASDAQ:FORM), Corindus Vascular Robotics,...
Apr 19, 2018 08:00 am ET
IQVIA™ Institute for Human Data Science Study: U.S. Prescription Opioid Volume Declined 12 Percent in 2017 – Largest Drop in 25 Years
The latest report from the IQVIA™ Institute for Human Data Science found prescription opioid dosage volume — as defined by Morphine Milligram Equivalents (MME) — declined 12 percent in 2017, marking the largest annual drop in more than 25 years of measurement.
Apr 18, 2018 04:15 pm ET
IQVIA to Announce First-Quarter 2018 Results on May 2, 2018
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), will announce its first-quarter 2018 financial results before the market opens on Wednesday, May 2, 2018. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Mar 15, 2018 03:00 am ET
IQVIA Establishes Alliance with MuleSoft to Deliver Innovative Integration Technology to Life Sciences Companies
IQVIA (NYSE: IQV), a company dedicated to using analytics and science to help healthcare stakeholders find better solutions for patients, today announced at the
Mar 14, 2018 03:00 am ET
IQVIA Forms Alliance with Box to Provide Revolutionary, Cloud-Based Content Management Solutions to the Life Sciences and Healthcare Industries
IQVIA™ (NYSE: IQV), a company dedicated to using analytics and science to help healthcare stakeholders find better solutions for patients, today announced at the eyeforpharma conference that it has entered into an alliance with
Mar 13, 2018 08:00 am ET
IQVIA Institute for Human Data Science Study: 10 Predictions for Innovation, Spending Drivers and Societal Value of Medicines that Will Transform Global Healthcare in 2018 and Beyond
According to a new report from the IQVIA™ Institute for Human Data Science, the types of medicines being developed, the way technology contributes to health, and how the value of health is calculated are all changing dramatically.
Mar 12, 2018 01:01 pm ET
MDA Collaborates with IQVIA to Expand Disease Registry into the New MOVR Data Hub
CHICAGO, March 12, 2018 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association (MDA) is enhancing and expanding its disease registry into a comprehensive data hub as part of a new initiative with IQVIA (NYSE: IQV), a company known worldwide for its expertise in cutting-edge information management, analytics and technology. The new initiative will be called the MOVR (NeuroMuscular ObserVational Research) Data Hub. The enhancements will capitalize on improvements in health care information technology and systemically unify and aggregate both clinical and genetics data with patient-repor...
Feb 27, 2018 08:10 am ET
New Research: Key Drivers of Growth for Mercury General, Quintiles Transitional, Texas Roadhouse, Chanticleer, Veeco Instruments, and PotlatchDeltic — Factors of Influence, Major Initiatives and Susta
NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mercury General Corporation (NYSE:MCY), Quintiles Transitional...
Feb 21, 2018 10:07 am ET
Cota Announces $40 Million Series C Financing to Advance its Cota Nodal Address™ Classification System and Real-World Evidence and Analytics Platforms
NEW YORK, Feb. 21, 2018 /PRNewswire/ -- Cota Inc., a healthcare real-world evidence and data analytics company bridging precision medicine to population health, today announced the completion of a Series C round of financing led by IQVIA (NYSE: IQV) with major participation by EW Healthcare Partners. ...
Feb 14, 2018 07:00 am ET
IQVIA Reports Fourth-Quarter and Full-Year 2017 Results, Issues First-Quarter and Full-Year 2018 Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients, today reported financial results for the quarter and full-year ended December 31, 2017. On October 3, 2016, the merger of Quintiles Transnational Holdings Inc. and IMS Health Holdings, Inc. was completed. To aid investors and analysts with year-over-year comparability for the merged business, we are
Feb 06, 2018 04:15 pm ET
IQVIA to Lead Group to Expand Safety/Efficacy Monitoring of Regulated Vaccines and Biologics for the FDA Center for Biologics Evaluation and Research
IQVIA Holdings Inc. (NYSE: IQV), a company dedicated to using analytics and science to help healthcare stakeholders find better solutions for patients, is announcing a novel alliance with the FDA Center for Biologics Evaluation and Research (CBER) to combine advanced analytics and unparalleled information assets to monitor and assist in the evaluation of safety and effectiveness of various CBER-regulated vaccines, blood products and other biologics.
Jan 31, 2018 04:15 pm ET
IQVIA to Announce Fourth-Quarter 2017 Results and Issue 2018 Guidance on February 14, 2018
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), will announce its fourth-quarter and full-year 2017 financial results and issue 2018 guidance before the market opens on Wednesday, February 14, 2018. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Jan 19, 2018 07:45 am ET
IQVIA Named to FORTUNE’s 2018 List of “World’s Most Admired Companies”
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) has once again been named to FORTUNE magazine’s “World’s Most Admired Companies” list. IQVIA received the distinction in FORTUNE’s Healthcare: Pharmacy and Other Services category with high marks in quality of management, value as a long-term investment, effectiveness in conducting business globally and wise use of corporate assets.
Dec 20, 2017 08:10 am ET
Market Trends Toward New Normal in Ashland Global, BioCryst Pharmaceuticals, PICO, Chicago Rivet & Machine, Mercury General, and IQVIA Holdings — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Dec. 20, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ashland Global Holdings Inc. (NYSE:ASH), BioCryst...
Dec 12, 2017 04:07 pm ET
IQVIA and Pierre Fabre Pharmaceuticals Expand Relationship to Deploy IQVIA’s Orchestrated Customer Engagement
IQVIA (NYSE:IQV), a company dedicated to using analytics and science to help healthcare stakeholders find better solutions for patients, and
Dec 12, 2017 08:00 am ET
IQVIA Launches Orchestrated Customer Engagement
IQVIA (NYSE:IQV), a company dedicated to using analytics and science to help healthcare stakeholders find better solutions for patients, today announced the launch of a new commercial technology solution,
Nov 28, 2017 08:00 am ET
IQVIA Announces Pricing of Secondary Public Offering
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) announced today the pricing of an underwritten, secondary public offering of 10,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc., investment funds associated with Bain Capital Investors, LLC, and Leonard Green & Partners, L.P. (the “Selling Stockholders”). IQVIA intends to repurchase from the underwriter 2,500,000 shares (the “Repurchase”). The Repurchase will be completed outside IQVIA’s exist
Nov 27, 2017 04:39 pm ET
IQVIA Announces Launch of Secondary Public Offering and Repurchase of Common Stock
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) announced today the launch of an underwritten, secondary public offering of 10,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc., investment funds associated with Bain Capital Investors, LLC, and Leonard Green & Partners, L.P. (the “Selling Stockholders”), of which IQVIA intends to repurchase from the underwriter 2,500,000 shares (the “Repurchase”). The Repurchase will be completed outside IQVIA